Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Rises By 5.7%

Aura Biosciences, Inc. (NASDAQ:AURA) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,300,000 shares, an increase of 5.7% from the August 15th total of 1,230,000 shares. Approximately 3.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 174,700 shares, the short-interest ratio is currently 7.4 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AURA. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. JMP Securities boosted their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Aura Biosciences in a research note on Friday.

Aura Biosciences Trading Down 1.0 %

NASDAQ:AURA opened at $9.97 on Tuesday. The company has a 50-day moving average of $8.58 and a 200-day moving average of $7.87. The firm has a market cap of $493.94 million, a price-to-earnings ratio of -5.36 and a beta of 0.35. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.35.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. On average, research analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. American Century Companies Inc. purchased a new position in Aura Biosciences in the 2nd quarter worth about $119,000. American International Group Inc. increased its position in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after acquiring an additional 3,782 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Aura Biosciences in the first quarter worth approximately $144,000. Trexquant Investment LP raised its holdings in shares of Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock valued at $154,000 after acquiring an additional 6,809 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares in the last quarter. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.